Suppression of CB1 Cannabinoid Receptor by Lentivirus Mediated Small Interfering RNA Ameliorates Hepatic Fibrosis in Rats

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Chen, Si Wen ^a   Wu, Ben Yan ^a   Xu, Shi Ping ^a   Fan, Ke Xing ^b   Yan, Li ^a   Gong, Yuan ^a   Wen, Jun Bao ^a   Wu, Dao Hong ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; ALPHA SMOOTH MUSCLE ACTIN; CANNABINOID 1 RECEPTOR; DIMETHYLNITROSAMINE; LENTIVIRUS VECTOR; SMAD PROTEIN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR SNAIL; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; TRANSFORMING GROWTH FACTOR BETA1; UVOMORULIN; VIMENTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; GENE EXPRESSION REGULATION; GENE REPRESSION; INTRACELLULAR SIGNALING; LENTIVIRINAE; LIVER FIBROSIS; MALE; MESENCHYME CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; RAT; SIGNAL TRANSDUCTION; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; APOPTOSIS; CADHERINS; CELL PROLIFERATION; EPITHELIAL-MESENCHYMAL TRANSITION; HEPATIC STELLATE CELLS; LIVER; LIVER CIRRHOSIS; MALE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, CANNABINOID, CB1; RNA, SMALL INTERFERING;

GASTROPODA; LENTIVIRUS; RATTUS;

EID: 84871216864     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0050850     Document Type: Article

References (36)

1. Fallowfield JA, (2011) Therapeutic targets in liver fibrosis. Am J Physiol Gastrointest Liver Physiol 300: G709-715.
2. Reichenbach V, Ros J, Fernández-Varo G, Casals G, Melgar-Lesmes P, et al. (2012) Prevention of Fibrosis Progression in CCl4-Treated Rats: Role of the Hepatic Endocannabinoid and Apelin Systems. J Pharmacol Exp Ther 340: 629-637.
3. Mallat A, Teixeira-Clerc F, Deveaux V, Manin S, Lotersztajn S, (2011) The endocannabinoid system as a key mediator during liver diseases: new insights and therapeutic openings. Br J Pharmacol 163: 1432-1440.
4. Huang L, Quinn MA, Frampton GA, Golden LE, DeMorrow S, (2011) Recent advances in the understanding of the role of the endocannabinoid system in liver diseases. Dig Liver Dis 43: 188-193.
5. Yang YY, Lee KC, Huang YT, Lee FY, Chau GY, et al. (2009) Inhibition of hepatic tumour necrosis factor-alpha attenuates the anandamide-induced vasoconstrictive response in cirrhotic rat livers. Liver Int 29: 678-685.
6. Domenicali M, Caraceni P, Giannone F, Pertosa AM, Principe A, et al. (2009) Cannabinoid type 1 receptor antagonism delays ascites formation in rats with cirrhosis. Gastroenterology 137: 341-349.
7. Magen I, Avraham Y, Berry E, Mechoulam R, (2008) Endocannabinoids in liver disease and hepatic encephalopathy. Curr Pharm Des 14: 2362-2369.
8. Di Marzo V, (2009) The endocannabinoid system: its general strategy of action, tools for its pharmacological manipulation and potential therapeutic exploitation. Pharmacol Res 60: 77-84.
9. Teixeira-Clerc F, Belot MP, Manin S, Deveaux V, Cadoudal T, et al. (2010) Beneficial paracrine effects of cannabinoid receptor 2 on liver injury and regeneration. Hepatology 52: 1046-1059.
10. Mukhopadhyay B, Liu J, Osei-Hyiaman D, Godlewski G, Mukhopadhyay P, et al. (2010) Transcriptional regulation of cannabinoid receptor-1 expression in the liver by retinoic acid acting via retinoic acid receptor-gamma. J Biol Chem 285: 19002-19011.
11. Mukhopadhyay B, Cinar R, Yin S, Liu J, Tam J, et al. (2011) Hyperactivation of anandamide synthesis and regulation of cell-cycle progression via cannabinoid type 1 (CB1) receptors in the regenerating liver. Proc Natl Acad Sci U S A 108: 6323-6328.
12. Kano M, Ohno-Shosaku T, Hashimotodani Y, Uchigashima M, Watanabe M, (2009) Endocannabinoid-mediated control of synaptic transmission. Physiol Rev 89: 309-380.
13. Wasmuth HE, Trautwein C, (2007) CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis. Hepatology 45: 543-544.
14. Racine-Samson L, Rockey DC, Bissell DM, (1997) The role of alpha1beta1 integrin in wound contraction. A quantitative analysis of liver myofibroblasts in vivo and in primary culture. J Biol Chem 272: 30911-30917.
15. Kaimori A, Potter J, Kaimori JY, Wang C, Mezey E, et al. (2007) Transforming growth factor-beta1 induces an epithelial-to-mesenchymal transition state in mouse hepatocytes in vitro. J Biol Chem 282: 22089-22101.
16. Choi SS, Diehl AM, (2009) Epithelial-to-mesenchymal transitions in the liver. Hepatology 50: 2007-2013.
17. Tam J, Liu J, Mukhopadhyay B, Cinar R, Godlewski G, et al. (2011) Endocannabinoids in liver disease. Hepatology 53: 346-355.
18. Bi WR, Yang CQ, Shi Q, (2012) Transforming Growth Factor-β1 Induced Epithelial-Mesenchymal Transition in Hepatic Fibrosis. Hepatogastroenterology 59 (118): [Epub ahead of print].
19. Friedman SL, (2008) Mechanisms of hepatic fibrogenesis. Gastroenterology 134: 1655-1669.
20. Derynck R, Zhang YE, (2003) Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 425: 577-584.
21. Qi Z, Atsuchi N, Ooshima A, Takeshita A, Ueno H, (1999) Blockade of type beta transforming growth factor signaling prevents liver fibrosis and dysfunction in the rat. Proc Natl Acad Sci U S A 96: 2345-2349.
22. George J, Roulot D, Koteliansky VE, Bissell DM, (1999) In vivo inhibition of rat stellate cell activation by soluble transforming growth factor beta type II receptor: A potential new therapy for hepatic fibrosis. Proc Natl Acad Sci U S A 96: 12719-12724.
23. Kalluri R, Weinberg RA, (2009) The basics of epithelial-mesenchymal transition. J Clin Invest 119: 1420-1428.
24. Yue HY, Yin C, Hou JL, Zeng X, Chen YX, et al. (2010) Hepatocyte nuclear factor 4alpha attenuates hepatic fibrosis in rats. Gut 59: 236-246.
25. Ikegami T, Zhang Y, Matsuzaki Y, (2007) Liver fibrosis: possible involvement of EMT. Cells Tissues Organs 185: 213-221.
26. Robertson H, Kirby JA, Yip WW, Jones DE, Burt AD, (2007) Biliary epithelial-mesenchymal transition in posttransplantation recurrence of primary biliary cirrhosis. Hepatology 45: 977-981.
27. Fabris L, Strazzabosco M, (2011) Epithelial-mesenchymal interactions in biliary diseases. Semin Liver Dis 31: 11-32.
28. Peinado H, Olmeda D, Cano A, (2007) Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype. Nat Rev Cancer 7: 415-428.
29. Povero D, Busletta C, Novo E, di Bonzo LV, Cannito S, et al. (2010) Liver fibrosis: a dynamic and potentially reversible process. Histol Histopathol 25: 1075-1091.
30. Gressner OA, Weiskirchen R, Gressner AM, (2007) Evolving concepts of liver fibrogenesis provide new diagnostic and therapeutic options. Comp Hepatol 6: 7.
31. Jeong WI, Osei-Hyiaman D, Park O, Liu J, Batkai S, et al. (2008) Paracrine activation of hepatic CB1 receptors by stellate cell-derived endocannabinoids mediates alcoholic fatty liver. Cell Metab 7: 227-235.
32. Zeisberg M, Yang C, Martino M, Duncan MB, Rieder F, et al. (2007) Fibroblasts derive from hepatocytes in liver fibrosis via epithelial to mesenchymal transition. J Biol Chem 282: 23337-23347.
33. Cho IJ, Kim YW, Han CY, Kim EH, Anderson RA, et al. (2010) E-Cadherin Antagonizes Transforming Growth Factor β1 Gene Induction in Hepatic Stellate Cells by Inhibiting RhoA-Dependent Smad3 Phosphorylation. Hepatology 52: 2053-2064.
34. Siegmund SV, Qian T, de Minicis S, Harvey-White J, Kunos G, et al. (2007) The endocannabinoid 2-arachidonoyl glycerol induces death of hepatic stellate cells via mitochondrial reactive oxygen species. FASEB J 21: 2798-2806.
35. Lim MP, Devi LA, Rozenfeld R, (2011) Cannabidiol causes activated hepatic stellate cell death through a mechanism of endoplasmic reticulum stress-induced apoptosis. Cell Death Dis 2: e170.
36. Yang YY, Lin HC, Huang YT, Lee TY, Hou MC, et al. (2007) Effect of chronic CB1 cannabinoid receptor antagonism on livers of rats with biliary cirrhosis. Clin Sci (Lond) 112: 533-542.